Literature DB >> 25730371

GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways.

Naoki Urakawa1, Soken Utsunomiya2, Mari Nishio2, Manabu Shigeoka3, Nobuhisa Takase1, Noriaki Arai2, Yoshihiro Kakeji4, Yu-ichiro Koma2, Hiroshi Yokozaki2.   

Abstract

Tumor-associated macrophages (TAMs) are known to be involved in the progression, angiogenesis, and motility of various cancers. We previously reported the association between an increased number of infiltrating TAMs with tumor progression and poor prognosis in esophageal squamous cell carcinomas (ESCCs). To study the roles of TAMs in ESCC, we first exposed peripheral blood monocyte (PBMo)-derived macrophages from healthy volunteers to conditioned media of TE series human ESCC cell line (TECM) and confirmed the induction of the expression of the M2 macrophage marker CD204 and the protumorigenic factors interleukin (IL)-10, VEGFA, and MMPs. Next, we compared gene expression profiles between PBMo-derived macrophages stimulated with or without TECM by cDNA microarray and focused on growth differentiation factor 15 (GDF15) among the highly expressed genes including IL-6, IL-8, and CXCL1. Our immunohistochemical study of 70 surgically resected ESCCs revealed that GDF15 was present not only in cancer cells but also in macrophages. The high expression of GDF15 in the ESCCs was significantly correlated with several more malignant phenotypes including vessel invasion, lymph node metastasis, and clinical stages. Patients with high GDF15 expression showed significantly poorer disease-free survival (P=0.011) and overall survival (P=0.041). We also found that recombinant human GDF15 promotes cell proliferation and the phosphorylation of both Akt and Erk1/2 in ESCC cell lines in vitro. These results indicate that GDF15 is secreted by both TAMs and cancer cells in the tumor microenvironment and is associated with aberrant growth and a poor prognosis in human ESCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25730371     DOI: 10.1038/labinvest.2015.36

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  47 in total

1.  MicroRNA-21 promotes the proliferation and inhibits apoptosis in Eca109 via activating ERK1/2/MAPK pathway.

Authors:  Fengxia Liu; Shutao Zheng; Tao Liu; Qing Liu; Meng Liang; Xiuling Li; Ilyar Sheyhidin; Xiaomei Lu; Wenya Liu
Journal:  Mol Cell Biochem       Date:  2013-05-25       Impact factor: 3.396

2.  Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression.

Authors:  P X Li; J Wong; A Ayed; D Ngo; A M Brade; C Arrowsmith; R C Austin; H J Klamut
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

3.  Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family.

Authors:  V M Paralkar; A L Vail; W A Grasser; T A Brown; H Xu; S Vukicevic; H Z Ke; H Qi; T A Owen; D D Thompson
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

Review 4.  Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

5.  Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma.

Authors:  Horlad Hasita; Yoshihiro Komohara; Hirohisa Okabe; Toshiro Masuda; Koji Ohnishi; Xiao F Lei; Toru Beppu; Hideo Baba; Motohiro Takeya
Journal:  Cancer Sci       Date:  2010-05-12       Impact factor: 6.716

6.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

7.  Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.

Authors:  Y Komohara; K Ohnishi; J Kuratsu; M Takeya
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

8.  Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.

Authors:  Dong Hoon Lee; Young Yang; Soon Jung Lee; Kun-Yong Kim; Tae Hyeon Koo; Sun Mi Shin; Kyu Sang Song; Young Ho Lee; Yung-Jin Kim; Jung Joon Lee; Inpyo Choi; Jeong-Hyung Lee
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

9.  Growth differentiation factor 15 is induced by hepatitis C virus infection and regulates hepatocellular carcinoma-related genes.

Authors:  Youhui Si; Xiuying Liu; Min Cheng; Maorong Wang; Qiaoling Gong; Yang Yang; Tianyi Wang; Wei Yang
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

10.  Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer.

Authors:  R J E Skipworth; D A C Deans; B H L Tan; K Sangster; S Paterson-Brown; D A Brown; M Hunter; S N Breit; J A Ross; K C H Fearon
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

View more
  34 in total

Review 1.  Growth differentiation factor 15 (GDF15) in cancer cell metastasis: from the cells to the patients.

Authors:  Anna Spanopoulou; Vasiliki Gkretsi
Journal:  Clin Exp Metastasis       Date:  2020-06-05       Impact factor: 5.150

2.  The interplay of growth differentiation factor 15 (GDF15) expression and M2 macrophages during prostate carcinogenesis.

Authors:  Sudha M Sadasivan; Yalei Chen; Nilesh S Gupta; Xiaoxia Han; Kevin R Bobbitt; Dhananjay A Chitale; Sean R Williamson; Andrew G Rundle; Deliang Tang; Benjamin A Rybicki
Journal:  Carcinogenesis       Date:  2020-08-12       Impact factor: 4.944

Review 3.  Ubiquitous Neural Cell Adhesion Molecule (NCAM): Potential Mechanism and Valorisation in Cancer Pathophysiology, Drug Targeting and Molecular Transductions.

Authors:  S Sowparani; P Mahalakshmi; J Pushpa Sweety; Arul Prakash Francis; U M Dhanalekshmi; N Selvasudha
Journal:  Mol Neurobiol       Date:  2022-07-12       Impact factor: 5.682

Review 4.  Macrophage inhibitory cytokine-1 in cancer: Beyond the cellular phenotype.

Authors:  Sakthivel Muniyan; Ramesh Pothuraju; Parthasarathy Seshacharyulu; Surinder K Batra
Journal:  Cancer Lett       Date:  2022-03-26       Impact factor: 9.756

5.  Small cell lung cancer: Recruitment of macrophages by circulating tumor cells.

Authors:  Gerhard Hamilton; Barbara Rath; Lukas Klameth; Maximilan J Hochmair
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

6.  IMP1 suppresses breast tumor growth and metastasis through the regulation of its target mRNAs.

Authors:  Guangli Wang; Zhenqiang Huang; Xin Liu; Wenhe Huang; Shaoying Chen; Yanchun Zhou; Deling Li; Robert H Singer; Wei Gu
Journal:  Oncotarget       Date:  2016-03-29

7.  Close Association of Intraepithelial Accumulation of M2-Skewed Macrophages with Neoplastic Epithelia of the Esophagus.

Authors:  Yumi Ichihara; Hiroshi Yokozaki
Journal:  Kobe J Med Sci       Date:  2021-06-18

8.  GDF15 promotes EMT and metastasis in colorectal cancer.

Authors:  Chen Li; Jingyu Wang; Jianlu Kong; Jinlong Tang; Yihua Wu; Enping Xu; Honghe Zhang; Maode Lai
Journal:  Oncotarget       Date:  2016-01-05

9.  p-Hydroxylcinnamaldehyde induces the differentiation of oesophageal carcinoma cells via the cAMP-RhoA-MAPK signalling pathway.

Authors:  Ming Ma; Lian-Mei Zhao; Xing-Xiao Yang; Ya-Nan Shan; Wen-Xuan Cui; Liang Chen; Bao-En Shan
Journal:  Sci Rep       Date:  2016-08-09       Impact factor: 4.379

10.  Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development.

Authors:  Okito Hashimoto; Makiko Yoshida; Yu-Ichiro Koma; Tomoko Yanai; Daiichiro Hasegawa; Yoshiyuki Kosaka; Noriyuki Nishimura; Hiroshi Yokozaki
Journal:  J Pathol       Date:  2016-09-19       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.